Literature DB >> 23690001

Genetic association between APOA1 and APOD polymorphisms and Alzheimer's disease in a Japanese population.

Nobuto Shibata1, Tomoyuki Nagata, Shunichiro Shinagawa, Tohru Ohnuma, Hiromi Shimazaki, Miwa Komatsu, Bolati Kuerban, Katrin Tomson, Kazuhiko Nakayama, Hisashi Yamada, Heii Arai.   

Abstract

Alterations in lipoproteins are involved in the pathophysiology of Alzheimer's disease (AD). For sporadic AD, the Apolipoprotein E (APOE) is recognized as a sole genetic risk factor. Apolipoprotein A1 (APOA1) has been suggested to bind amyloid β and promoter polymorphisms of the APOA1 gene were likely to affect the onset of the disease. Apolipoprotein D (APOD) expression is upregulating in AD brain and evidences showed APOD polymorphisms affect the risk for AD. The aim of this study was to investigate whether polymorphisms of both APOA1 and APOD genes are associated with early-onset AD (EOAD) and late-onset AD (LOAD). Common single nucleotide polymorphisms (SNPs) of the two genes were analyzed using a case-control study design. There were no associations between the two SNPs of the APOA1 gene and the onset of AD. No synergetic associations were found among the APOA1 SNPs, APOE and the risk for AD. Rs7659, 3' UTR polymorphism of the APOD gene was associated with EOAD in APOEε4 (-) subgroup. We were unable to show any impact of the other two SNPs of the APOD gene on the risk for AD. Our results suggest that the variation of the APOD gene modifies the risk for AD. Further association studies for APOD 3' UTR polymorphisms with other ethnic groups would be needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690001     DOI: 10.1007/s00702-013-1036-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

1.  Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity.

Authors:  R P Koldamova; I M Lefterov; M I Lefterova; J S Lazo
Journal:  Biochemistry       Date:  2001-03-27       Impact factor: 3.162

2.  Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits.

Authors:  Ana Navarro; Eva Del Valle; Aurora Astudillo; Carmen González del Rey; Jorge Tolivia
Journal:  Exp Neurol       Date:  2003-12       Impact factor: 5.330

3.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

4.  Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease.

Authors:  Yan Chen; Longfei Jia; Cuibai Wei; Fen Wang; Haiyan Lv; Jianping Jia
Journal:  Brain Res       Date:  2008-07-12       Impact factor: 3.252

5.  Amyloid-β25-35 induces apolipoprotein D Synthesis and growth arrest in HT22 hippocampal cells.

Authors:  Eva Martínez; Ana Navarro; Cristina Ordóñez; Eva Del Valle; Jorge Tolivia
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Gender differences in apolipoprotein D expression during aging and in Alzheimer disease.

Authors:  Cristina Ordóñez; Ana Navarro; Cristina Pérez; Eva Martínez; Eva del Valle; Jorge Tolivia
Journal:  Neurobiol Aging       Date:  2011-03-22       Impact factor: 4.673

7.  Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Authors:  Terry L Lewis; Dongfeng Cao; Hailin Lu; Robert A Mans; Yan Ru Su; Lisa Jungbauer; MacRae F Linton; Sergio Fazio; Mary Jo LaDu; Ling Li
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

8.  Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype.

Authors:  F Glöckner; T G Ohm
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans.

Authors:  Purnima P Desai; Hugh C Hendrie; Rebecca M Evans; Jill R Murrell; Steven T DeKosky; M Ilyas Kamboh
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-01-01       Impact factor: 3.568

10.  Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals.

Authors:  Fei Song; Anne Poljak; John Crawford; Nicole A Kochan; Wei Wen; Barbara Cameron; Ora Lux; Henry Brodaty; Karen Mather; George A Smythe; Perminder S Sachdev
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

View more
  6 in total

1.  Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer's disease: the National Finnish population study (FINRISK).

Authors:  Juho Tynkkynen; Jussi A Hernesniemi; Tiina Laatikainen; Aki S Havulinna; Jouko Sundvall; Jaana Leiviskä; Perttu Salo; Veikko Salomaa
Journal:  Age (Dordr)       Date:  2016-09-23

Review 2.  Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain.

Authors:  Sarah Dassati; Andreas Waldner; Rüdiger Schweigreiter
Journal:  Neurobiol Aging       Date:  2014-02-05       Impact factor: 4.673

3.  Variations in apolipoprotein D and sigma non-opioid intracellular receptor 1 genes with relation to risk, severity and outcome of ischemic stroke.

Authors:  Håkan Lövkvist; Ann-Cathrin Jönsson; Holger Luthman; Katarina Jood; Christina Jern; Tadeusz Wieloch; Arne Lindgren
Journal:  BMC Neurol       Date:  2014-09-28       Impact factor: 2.474

Review 4.  Functional Roles of the Interaction of APP and Lipoprotein Receptors.

Authors:  Theresa Pohlkamp; Catherine R Wasser; Joachim Herz
Journal:  Front Mol Neurosci       Date:  2017-03-01       Impact factor: 5.639

5.  The pleiotropic vasoprotective functions of high density lipoproteins (HDL).

Authors:  Guilaine Boyce; Emily Button; Sonja Soo; Cheryl Wellington
Journal:  J Biomed Res       Date:  2017-05-26

6.  Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.

Authors:  Qiao Lin; Yunpeng Cao; Jie Gao
Journal:  Drug Des Devel Ther       Date:  2015-09-29       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.